1-5 of 5
Peter Rosen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

Clinical Trials & Observations
Ravi Vij, Michael Wang, Jonathan L. Kaufman, Sagar Lonial, Andrzej J. Jakubowiak, A. Keith Stewart, Vishal Kukreti, Sundar Jagannath, Kevin T. McDonagh, Melissa Alsina, Nizar J. Bahlis, Frederic J. Reu, Nashat Y. Gabrail, Andrew Belch, Jeffrey V. Matous, Peter Lee, Peter Rosen, Michael Sebag, David H. Vesole, Lori A. Kunkel, Sandra M. Wear, Alvin F. Wong, Robert Z. Orlowski, David S. Siegel
Journal: Blood
Blood (2012) 119 (24): 5661–5670.
https://doi.org/10.1182/blood-2012-03-414359
Published: 2012
Journal Articles

A Phase 2 Study of INCB018424, An Oral, Selective JAK1/JAK2 Inhibitor, in Patients with Advanced Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory to Hydroxyurea.

Srdan Verstovsek, MD, PhD, Francesco Passamonti, Alessandro Rambaldi, MD, Giovanni Barosi, MD, Peter Rosen, MD, Richard Levy, MD, Edward C Bradley, MD, Lee Schacter, William M Garrett, MBA, Kris Vaddi, Ph.D., Nancy Contel, Elisa Rumi, Elisabetta Gattoni, MD, Mario Cazzola, Hagop Kantarjian, Tiziano Barbui, Alessandro Vannucchi
Journal: Blood
Blood (2009) 114 (22): 311.
https://doi.org/10.1182/blood.V114.22.311.311
Published: 2009
Journal Articles

Bortezomib, Bendamustine, and Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma: Encouraging Activity in the Phase 2 VERTICAL Study.

Nathan Fowler, Brad S Kahl, Peter Rosen, Jeffrey Matous, Amanda Cashen, Samuel Jacobs, Jeffrey Letzer, Bipinkumar Amin, Michael Williams, Maureen Ross, Sonali Smith, Alfred Saleh, Hongliang Shi, Sudha Parasuraman, Bruce D. Cheson
Journal: Blood
Blood (2009) 114 (22): 933.
https://doi.org/10.1182/blood.V114.22.933.933
Published: 2009
Journal Articles

Phase II Study of Denileukin Diftitox (ONTAK®) in Patients with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (B-NHL) and Poor Bone Marrow Reserve.

Myron S. Czuczman, MD, Lauren Pinter-Brown, Mary Jo Lechowicz, Nancy Bartlett, MD, Hillard Lazarus, John Lister, Andre Goy, MD, Stephen Kahanic, MD, Peter Rosen, MD, Mark Acosta, PharmD
Journal: Blood
Blood (2006) 108 (11): 4724.
https://doi.org/10.1182/blood.V108.11.4724.4724
Published: 2006
Journal Articles

Prior Autologous Hematopoietic Cell Transplantation Confers an Adverse Prognosis for Recipients of Allogeneic Transplantation Following Nonmyeloablative Preparative Conditioning.

Gary J. Schiller, M.D., Christos Emmanouilides, M.D., Ron Paquette, M.D., Peter Rosen, M.D., Jennifer Gansert, M.D., Ph.D., Mary C. Territo, M.D.
Journal: Blood
Blood (2004) 104 (11): 5054.
https://doi.org/10.1182/blood.V104.11.5054.5054
Published: 2004